Eli Lilly CEO David Ricks steps away from the podium at the White House in May 2020 (Evan Vucci/AP Images)
Eli Lilly abandons its plans to pitch its blockbuster contender mirikizumab for psoriasis after sizing up heavyweight rivals
Last July, Eli Lilly execs had nothing but good things to say about the “promising” late-stage psoriasis data they had gathered together on their …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
